Plan the exit before the readout: strategic alternatives shouldn't start after a miss

Three outcomes, one week

Three small-cap stories filed on the same day describe very different endings. Longeveron reported that laromestrocel missed its primary endpoint in infants with hypoplastic left heart syndrome, and it is now seeking an FDA meeting while starting a strategic alternatives review that could end in a sale or merger. Theriva Biologics sold its SYN-004 antibiotic-enzyme assets to Biossil Labs for $350,000 upfront, while saying enrolment in its VIRAGE2 pancreatic cancer trial should finish in the fourth quarter of 2026. Silence Therapeutics reported positive Phase 2 divesiran data in polycythemia vera and $247.7M in cash, with a pending acquisition by Merck KGaA.

I am not suggesting these outcomes are directly comparable, or that the data alone explain them. Each company has its own history and its own asset. But the sequence matters. Silence has a deal pending alongside good data. Theriva is pruning on its own timetable. Longeveron is opening its review in the shadow of a miss. Optionality is widest before a binary event and narrowest right after a bad one.

The review that starts after the miss

A strategic alternatives review announced the same day as a failed pivotal readout tells the market that the company is now running two tracks: salvaging the asset with regulators, and finding a home for whatever is left. Longeveron's pairing of an FDA meeting with a sale-or-merger review is the sensible move. But the company is negotiating from the point where its bargaining position is weakest.

Theriva's $350,000 upfront is a useful marker of what a non-core asset can fetch when it is sold deliberately. It is a small sum, but the company converted a peripheral programme into cash and a clean focus on VIRAGE2 without being forced. The price is modest, but the discipline is the point.

Buyers are active, for the right assets

The week's other deals show demand is there for assets that fit. CorMedix agreed to buy substantially all of Heron's assets, adding four marketed drugs with about $150 million in trailing-12-month net revenue, backed by a Pharmakon term loan. Alcon announced its planned purchase of Neurotech. Lilly took worldwide estetrol combination rights from Gedeon Richter and will buy about $15M of Richter shares. Kiora in-licensed an oral calpain inhibitor from Senju, rights outside Asia, and has asked the FDA for a pre-IND meeting and orphan designation.

The buyers are not indiscriminate. They are paying for defined, usable things: marketed revenue, specific rights, a clear regulatory next step. A company that waits for a readout to decide what it is will find that the market sorts it quickly.

The strongest counter-argument

The best objection is that pre-planning an exit is its own signal. Investors and partners may read a board that is courting buyers before a pivotal readout as lacking conviction, and management attention is finite. There is also no guarantee that a buyer exists. Theriva's $350,000 shows that some assets sell for little however early the process starts. Silence's situation also reflects an asset class, RNAi, with its own buyer logic.

That is fair, but it confuses preparation with announcement. Boards can map the assets, partners and capital structure alternatives in advance without telling the market. What they cannot do is recreate leverage once a primary endpoint has been missed.

What it means

The industry talks about readouts as moments of truth for the science. They are also moments of truth for the balance sheet and the negotiating table. Companies that treat the strategic question as a post-failure exercise end up with the weakest hand just when they most need a good one. Those that prune, partner and prepare early keep choices open, whether the data are good or bad.